CEL-SCI Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

36.96M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Sep 30, 2023	-	-	-
Sep 30, 2022	-	-	-
Sep 30, 2021	-	-	-
Sep 30, 2020	558.66K	95.91K	20.73%
Sep 30, 2019	462.75K	-13.80K	-2.90%
Sep 30, 2018	Pro	Pro	Pro
Sep 30, 2017	Pro	Pro	Pro
Sep 30, 2016	Pro	Pro	Pro
Sep 30, 2015	Pro	Pro	Pro
Sep 30, 2014	Pro	Pro	Pro

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Outset Medical	114.73M
BioLineRx	17.05M
Accelerate Diagnostics	11.91M
LAVA Therapeutics	7.40M
Lexaria Bioscience	411.02K
Nexalin Technology	162.08K

Revenue Rankings

CVM News

13 days ago - Stock Picks From Seeking Alpha's October 2024 New Analysts - Seeking Alpha
14 days ago - U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 - Business Wire
4 weeks ago - FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients - Business Wire
7 weeks ago - CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer - Business Wire
2 months ago - CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - Business Wire
2 months ago - CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress - Business Wire
2 months ago - The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance - Business Wire
3 months ago - CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results - Business Wire

More News